Skip to content
COPD News Today logo
  • About COPD
    What is COPD?
    Causes
    Diagnosis
    Symptoms
  • Treatments
    Approved treatments
    Experimental treatments
    Non-drug therapies
  • News
  • Columns
    Life Tethered to a Concentrator – Caroline Gainer
  • Podcast
  • What can we help you find today?

Nucala (mepolizumab) for COPD

Last updated May 29, 2025, by Marisa Wexler, MS
✅ Fact-checked by Marta Figueiredo, PhD

Indications
Administration
Clinical trials
Side effects

 

What is Nucala for COPD?

Nucala (mepolizumab) is an injectable therapy approved in the U.S. for adults with poorly controlled chronic obstructive pulmonary disease (COPD) who have high counts of eosinophils, a type of immune cell.

The antibody-based therapy is used as an add-on maintenance treatment to reduce the risk of COPD exacerbations, or periods of sudden COPD symptom worsening.

Up to 40% of people with COPD have elevated eosinophils, which are involved in a form of inflammation, called type 2 inflammation, that is thought to contribute to COPD-related lung inflammation and exacerbations. Patients with high eosinophils in the blood and/or lungs have more severe disease and are at a higher risk of severe exacerbations.

Administered via under-the-skin, or subcutaneous, injections, GSK’s Nucala works by blocking the activity of interleukin-5 (IL-5), a signaling molecule that promotes the growth, maturation, and survival of eosinophils.

Therapy snapshot

Brand name: Nucala
Chemical name: Mepolizumab
Usage: Used as an add-on maintenance treatment to reduce risk of exacerbations in certain adults with COPD
Administration: Subcutaneous injection

 

Who can take Nucala?

Nucala is approved in the U.S. as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype (meaning high eosinophil counts).

It is not recommended for anyone with a history of allergic reaction to the therapy or any of its ingredients.

The medication also should not be used to manage acute symptoms or acute exacerbations of COPD, or to treat acute bronchospasm (a tightening of lung muscles that narrows the airways, making it difficult to breathe).

How is Nucala administered in COPD?

Nucala is given by under-the-skin injections, which should be done under the guidance of a healthcare professional. The therapy’s prefilled autoinjector and prefilled syringe versions can be used by patients and their caregivers after appropriate training.

The recommended dosage for COPD is 100 mg every four weeks.

Nucala in clinical trials

Nucala’s approval in the U.S. was based on data from two Phase 3 clinical trials that collectively enrolled more than 1,600 adults with inadequately controlled COPD and an eosinophilic phenotype. Participants were randomly assigned to receive either Nucala or a placebo, in addition to standard triple inhaled therapy, consisting of a corticosteroid and two bronchodilators (medications that widen the airways), for one year.

Both studies showed that, relative to the placebo, one year of Nucala treatment significantly reduced annualized rates of moderate or severe exacerbations:

  • by 21% in the MATINEE study (NCT04133909)
  • by 18% in the METREX trial (NCT02105948).

In MATINEE, Nucala treatment was also associated with a significantly lower risk of moderate or severe exacerbation, by 23%, and a 35% lower annualized rate of exacerbations requiring emergency department visits and/or hospitalization.

In both MATINEE and METREX, patient-reported measures of life quality and symptom severity were not significantly different between the Nucala and placebo groups.

Nucala side effects

Most side effects observed with Nucala in people with COPD are mild to moderate in severity. The most common ones include:

  • back pain
  • diarrhea
  • cough.

Nucala also may cause other safety issues including:

  • allergic reactions
  • higher susceptibility to infection with herpes zoster (the virus that causes chickenpox and shingles) and certain parasites called helminths or worms.

These may necessitate safety precautions like monitoring, pre-treatment vaccination, and Nucala treatment delay.

Also, corticosteroids should not be abruptly discontinued upon initiation of Nucala treatment, because it can cause dangerous reactions. Instead, dosage of corticosteroids should be gradually reduced under the guidance of a healthcare professional.


COPD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Recent Posts

  • With COPD, I harvest health from my raised garden bed September 2, 2025
  • Relief from my arthritis is a breath of fresh air August 26, 2025
  • New survey reveals key barriers to care for COPD patients in US August 25, 2025
  • Brewing up ‘magic coffee’ keeps me strong and breathing well August 19, 2025
  • ‘Stay busy. Be useful.’ is a great mantra for those living with COPD August 12, 2025
  • For living well with COPD, I rely on these tips, tricks, and gadgets August 5, 2025
  • A change in health can sometimes seem like a landslide July 29, 2025
  • 2 global trials show mixed results for astegolimab for treating COPD July 28, 2025
  • Are telehealth visits the new doctor home visits? July 22, 2025
  • Is it getting harder to coordinate our care? July 1, 2025


Related articles

  1. Main banner for Caroline Gainer's column,
    September 2, 2025 by Caroline Gainer

    With COPD, I harvest health from my raised garden bed

  2. Main banner for Caroline Gainer's column,
    August 26, 2025 by Caroline Gainer

    Relief from my arthritis is a breath of fresh air

  3. A magnifying glass hovers over a ticked box on a survey form with both checked and unchecked boxes.
    August 25, 2025 News by Margarida Maia, PhD

    New survey reveals key barriers to care for COPD patients in US

  4. Main banner for Caroline Gainer's column,
    August 19, 2025 by Caroline Gainer

    Brewing up ‘magic coffee’ keeps me strong and breathing well

  5. Main banner for Caroline Gainer's column,
    August 12, 2025 by Caroline Gainer

    ‘Stay busy. Be useful.’ is a great mantra for those living with COPD

  6. Main banner for Caroline Gainer's column,
    August 5, 2025 by Caroline Gainer

    For living well with COPD, I rely on these tips, tricks, and gadgets

Swipe left to view more
Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.